193 related articles for article (PubMed ID: 33990705)
41. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
42. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
43. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
[TBL] [Abstract][Full Text] [Related]
44. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
[TBL] [Abstract][Full Text] [Related]
45. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
46. Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review.
McKeague SJ; O'Rourke K; Fanning S; Joy C; Throp D; Adams R; Harvey Y; Keng TB
Am J Clin Pathol; 2024 Feb; 161(2):197-205. PubMed ID: 37855739
[TBL] [Abstract][Full Text] [Related]
47. Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.
Zaremba CM; Oliver D; Cavalier M; Fuda F; Karandikar NJ; Chen W
Ann Diagn Pathol; 2012 Jan; 16(1):16-20. PubMed ID: 22050963
[TBL] [Abstract][Full Text] [Related]
48. Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).
Aljabry MS
J Hematop; 2023 Mar; 16(1):27-31. PubMed ID: 38175368
[TBL] [Abstract][Full Text] [Related]
49. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
[TBL] [Abstract][Full Text] [Related]
50. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
51. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
Munthe-Kaas MC; Forthun RB; Brendehaug A; Eek AK; Høysæter T; Osnes LTN; Prescott T; Spetalen S; Hovland R
J Pediatr Hematol Oncol; 2021 May; 43(4):e508-e511. PubMed ID: 32852395
[TBL] [Abstract][Full Text] [Related]
52. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
[TBL] [Abstract][Full Text] [Related]
53. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
54. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.
Vu HA; Xinh PT; Masuda M; Motoji T; Toyoda A; Sakaki Y; Tokunaga K; Sato Y
Leukemia; 2006 Aug; 20(8):1414-21. PubMed ID: 16761019
[TBL] [Abstract][Full Text] [Related]
55. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):866-9. PubMed ID: 19698218
[TBL] [Abstract][Full Text] [Related]
56. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
Mod Pathol; 2020 Mar; 33(3):334-343. PubMed ID: 31471587
[TBL] [Abstract][Full Text] [Related]
57. Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes.
Choi JK; Xiao W; Chen X; Loghavi S; Elenitoba-Johnson KS; Naresh KN; Medeiros LJ; Czader M;
Mod Pathol; 2024 May; 37(5):100466. PubMed ID: 38460674
[TBL] [Abstract][Full Text] [Related]
58. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of
Baer C; Muehlbacher V; Kern W; Haferlach C; Haferlach T
Haematologica; 2018 Aug; 103(8):e348-e350. PubMed ID: 29567772
[No Abstract] [Full Text] [Related]
59. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
[TBL] [Abstract][Full Text] [Related]
60. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
